Locally Advanced Breast Cancer: Individualized Treatment Based On Tumor Molecular Characteristics
13 september 2018 uppdaterad av: NYU Langone Health
Paclitaxel 30 mg/m2 twice/week Trastuzumab 4mg/kg, loading dose, then 2 mg/kg weekly and Concurrent RT (to start within one week from first dose of Paclitaxel/Trastuzumab) to breast, supraclavicular, axillary fields, 45 Gy @ 1.8 Gy/fraction, + 14 Gy @ 2 Gy/fraction to the primary tumor. At the end of chemo-radiation, Trastuzumab will be continued weekly until surgery and as per standard of care after surgery for up to 1 year total.
**Surgery: Patients will undergo lumpectomy and axillary node dissection or modified radical mastectomy within two months following discontinuation of pre-operative systemic therapy, contingent upon recovery of skin toxicity. Pathologic response will be evaluated at the time of surgery. Additional tissue samples will be collected from the surgical specimen for assessment of tumor molecular characteristics.
***All patients may undergo four cycles of post-operative Standard AC (doxorubicin 60 mg/m2, cyclophosphamide 600 mg/m2) or four cycles of post-operative epirubicin and Cyclophosphamide (epirubicin 100 mg/m2, cyclophosphamide 600 mg/m2) if doxorubicin is not available Tamoxifen as well or any alternative antihormonal therapy may be prescribed for five years for patients with hormone receptor positive tumors. Herceptin (Trastuzumab) will be prescribed for a total of 1 year since first dose as per standard of care.
Studieöversikt
Status
Avslutad
Betingelser
Intervention / Behandling
Detaljerad beskrivning
Locally Advanced Breast Cancer: T greater than 3.0 cm.
HER-2/neu positive.
Patients with ipsilateral supraclavicular nodes are eligible.
Patients with inflammatory breast cancer or distant metastases are excluded.
Patients with prior treatment for their breast cancer are excluded.
Patients must have adequate laboratory parameters and normal cardiac function.
Patients receive Concurrent Radiation therapy with either Capecitabine, Paclitaxel and Herceptin.
Capecitabine (Xeloda®) 750 mg/m2 twice/daily given orally.
Treatment should begin on day 1 of radiation therapy.
The two doses should be taken about 30 minutes after eating (eg.
after breakfast and after dinner).
Treatment will be given for 10 weeks (for 6 weeks during radiation and for 4 weeks after radiation).Trastuzumab (Herceptin®) will begin on day 1 of radiation therapy and be administered weekly.
The first dose will be 4mg/kg given IV over 90 minutes.
Subsequent weekly doses will be 2 mg/kg/week IV over 30 minutes.
Paclitaxel 30 mg/m2 twice per week given IV over 1 hour.
Treatment will be initiated during the first week of radiation therapy and should be administered on a Monday/Thursday or Tuesday/Friday schedule.Paclitaxel 30 mg/m2 twice per week given IV over 1 hour.
Treatment will be initiated during the first week of radiation therapy and should be administered on a Monday/Thursday or Tuesday/Friday schedule.Trastuzumab (Herceptin®) treatment will be administered weekly, together with one of the two weekly doses of Paclitaxel.
The first dose will be 4mg/kg given IV over 90 minutes.
Subsequent weekly doses will be given at a dose of 2 mg/kg/week IV over 30 minutes.
The treatment with Trastuzumab will continue weekly after the completion of the radiation treatment until surgery and thereafter as per standard of care up to 1 year post surgery.
Studietyp
Interventionell
Inskrivning (Faktisk)
44
Fas
- Fas 2
- Fas 1
Kontakter och platser
Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.
Studieorter
-
-
New York
-
New York, New York, Förenta staterna, 10065
- Weill Medical College of Cornell University
-
-
Deltagandekriterier
Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.
Urvalskriterier
Åldrar som är berättigade till studier
18 år till 90 år (Vuxen, Äldre vuxen)
Tar emot friska volontärer
Nej
Kön som är behöriga för studier
Kvinna
Beskrivning
Inclusion Criteria:
- Biopsy proven locally advanced breast cancer: STAGE IIB (T must be > 3.0 cm, N0), IIIA (T0N2, T1N2, T2N2, T3N1), IIIB (T4N0-2).
- HER-2/neu positive ( DAKO 3+ by Immunohistochemistry or FISH positive if Dako 2+)
- Metastatic breast cancer: limited to the subset of patients with intact breast, locally advanced tumor and involved ipsilateral supraclavicular nodes.
- Measurable disease required according to the RECIST criteria (Response Evaluation Criteria in Solid Tumors)
- Adequate laboratory values:
- Hgb > 10
- ANC(Absolute Neutrophil Count) > 1500
- Platelets > 150,000
- Cr < 1.5
- Liver function < 3 X normal.
- Patient > 18 years of age.
- Medically and psychologically able to comply with all study requirements.
- ECOG (Eastern cooperative Oncology group) performance score 0-1.
- Signed informed consent.
Exclusion Criteria:
- Stage 0, Stage I, Stage IIA.
- Previous XRT(Radiation therapy) or chemotherapy.
- Presence of distant metastases documented clinically or radiographically with the exception of ipsilateral supraclavicular nodes.
- Inflammatory breast cancer.
- Prior unanticipated severe reaction to fluoropyrimidine therapy or known hypersensitivity to 5-fluorouracil.
- Exclude pregnant or lactating woman.
- Woman of childbearing potential with either a positive or no pregnancy test at baseline.
- Woman of childbearing potential not using a reliable and appropriate contraceptive method.
- (Postmenopausal women must have been amenorrheic for at least 12 months to be considered of non-childbearing potential).
- Patient will agree to continue contraception for 30 days from the date of the last study drug administration.
- Serious concurrent infections.
- Clinically significant cardiac disease not well controlled with medication (e.g. congestive heart failure, symptomatic coronary artery disease and cardiac arrhythmias ) or myocardial infarction within the last 12 months.
- Patients who have had an organ allograft.
- Patients with severe renal impairment (creatinine clearance below 30 mL/min [Cockcroft and Gault43]). In patients with moderate renal impairment (creatinine clearance 30-50 mL/min [Cockcroft and Gault43]) at baseline, a dose reduction to 75% of the XELODA starting dose is recommended. In patients with mild renal impairment (creatinine clearance 51-80 mL/min) no adjustment in starting dose is recommended.
- In phase I studies, those with any abnormal renal function, since toxicity will likely be affected by the presence of any significant renal dysfunction.
- Cockcroft and Gault Equation:
- (140 - age [yrs]) (body wt [kg])
- Creatinine clearance for males = --------------
- (72) (serum creatinine [mg/dL])
- Creatinine clearance for females = 0.85 x male value
Studieplan
Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Icke-randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: Arm 1 Capecitabine and RT
Her-2/neu negative patients will be given Capecitabine (xeloda, 750mg/m2 twice daily orally.
Treatment should begin on day 1 of radiation therapy.
The two doses should be taken about 30 minutes after eating (eg.
after breakfast and after dinner).
Treatment will be given for 10 weeks (for 6 weeks during radiation and for 4 weeks after radiation).
|
Concurrent RT (to start within one week from first dose of Paclitaxel/Trastuzumab) to breast, supraclavicular, axillary fields, 45 Gy @ 1.8 Gy/fraction, + 14 Gy @ 2 Gy/fraction to the primary tumor.
At the end of chemo-radiation, Trastuzumab will be continued weekly until surgery and as per standard of care after surgery for up to 1 year total.
Capecitabine (Xeloda®) 750 mg/m2 twice/daily given orally.
Treatment should begin on day 1 of radiation therapy.
The two doses should be taken about 30 minutes after eating (eg.
after breakfast and after dinner).
Treatment will be given for 10 weeks (for 6 weeks during radiation and for 4 weeks after radiation).
Andra namn:
|
|
Experimentell: Arm 2 Paclitaxel/Trastuzumab and RT
Trastuzumab (Herceptin®) will begin on day 1 of radiation therapy and be administered weekly to Her-2/neu Positive patients.
The first dose will be 4mg/kg given IV over 90 minutes.
Weekly doses will be 2 mg/kg/week IV over 30 minutes.Paclitaxel 30 mg/m2 twice per week given IV over 1 hour.
|
Concurrent RT (to start within one week from first dose of Paclitaxel/Trastuzumab) to breast, supraclavicular, axillary fields, 45 Gy @ 1.8 Gy/fraction, + 14 Gy @ 2 Gy/fraction to the primary tumor.
At the end of chemo-radiation, Trastuzumab will be continued weekly until surgery and as per standard of care after surgery for up to 1 year total.
Trastuzumab (Herceptin®) treatment will be administered weekly, together with one of the two weekly doses of Paclitaxel.
The first dose will be 4mg/kg given IV over 90 minutes.
Subsequent weekly doses will be given at a dose of 2 mg/kg/week IV over 30 minutes.
The treatment with Trastuzumab will continue weekly after the completion of the radiation treatment until surgery and thereafter as per standard of care up to 1 year post surgery.
Andra namn:
Paclitaxel 30 mg/m2 twice per week given IV over 1 hour.
Treatment will be administered on a Monday/Thursday or Tuesday/Friday schedule.The radiation treatment will start within 1 week from the first dose of paclitaxel and trastuzumab.
Pre-meds for paclitaxel should be based on the institutional standards; it is suggested that dexamethasone (Decadron®), 20 mg IV, be given with the first paclitaxel dose.
If the patient tolerates the treatment, the dexamethasone may be tapered and/or discontinued for subsequent doses.
Treatment will be given for 10 weeks (for 6 weeks during radiation and for 4 weeks following radiation).
Andra namn:
|
|
Experimentell: Arm 3: Paclitaxel and RT
Paclitaxel 30 mg/m2 twice per week given IV over 1 hour to Her-2/neu negative patients.
Treatment will be initiated during the first week of radiation therapy and should be administered on a Monday/Thursday or Tuesday/Friday schedule.
|
Concurrent RT (to start within one week from first dose of Paclitaxel/Trastuzumab) to breast, supraclavicular, axillary fields, 45 Gy @ 1.8 Gy/fraction, + 14 Gy @ 2 Gy/fraction to the primary tumor.
At the end of chemo-radiation, Trastuzumab will be continued weekly until surgery and as per standard of care after surgery for up to 1 year total.
Paclitaxel 30 mg/m2 twice per week given IV over 1 hour.
Treatment will be administered on a Monday/Thursday or Tuesday/Friday schedule.The radiation treatment will start within 1 week from the first dose of paclitaxel and trastuzumab.
Pre-meds for paclitaxel should be based on the institutional standards; it is suggested that dexamethasone (Decadron®), 20 mg IV, be given with the first paclitaxel dose.
If the patient tolerates the treatment, the dexamethasone may be tapered and/or discontinued for subsequent doses.
Treatment will be given for 10 weeks (for 6 weeks during radiation and for 4 weeks following radiation).
Andra namn:
|
|
Experimentell: Arm 4: Paclitaxel/Trastuzumab and RT
Trastuzumab (Herceptin®) tx will be administered weekly, together with one of the 2 weekly doses of Paclitaxel to Her-2/neu Positive patients.
The 1st dose will be 4mg/kg given IV over 90 minutes.
Weekly doses will b given at a dose of 2 17mg/kg/week IV over 30 minutes.
The Tx with Trastuzumab will continue weekly after the completion of the radiation tx until surgery & thereafter as per std of care up to 1 yr post surgery.Paclitaxel 30 mg/m2 twice per week given IV over 1 hour.
Tx will be administered on a Monday/Thursday or Tuesday/Friday schedule.The radiation treatment will start within 1 week from the first dose of paclitaxel and trastuzumab.
|
Concurrent RT (to start within one week from first dose of Paclitaxel/Trastuzumab) to breast, supraclavicular, axillary fields, 45 Gy @ 1.8 Gy/fraction, + 14 Gy @ 2 Gy/fraction to the primary tumor.
At the end of chemo-radiation, Trastuzumab will be continued weekly until surgery and as per standard of care after surgery for up to 1 year total.
Trastuzumab (Herceptin®) treatment will be administered weekly, together with one of the two weekly doses of Paclitaxel.
The first dose will be 4mg/kg given IV over 90 minutes.
Subsequent weekly doses will be given at a dose of 2 mg/kg/week IV over 30 minutes.
The treatment with Trastuzumab will continue weekly after the completion of the radiation treatment until surgery and thereafter as per standard of care up to 1 year post surgery.
Andra namn:
Paclitaxel 30 mg/m2 twice per week given IV over 1 hour.
Treatment will be administered on a Monday/Thursday or Tuesday/Friday schedule.The radiation treatment will start within 1 week from the first dose of paclitaxel and trastuzumab.
Pre-meds for paclitaxel should be based on the institutional standards; it is suggested that dexamethasone (Decadron®), 20 mg IV, be given with the first paclitaxel dose.
If the patient tolerates the treatment, the dexamethasone may be tapered and/or discontinued for subsequent doses.
Treatment will be given for 10 weeks (for 6 weeks during radiation and for 4 weeks following radiation).
Andra namn:
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Tidsram |
|---|---|
|
Feasibility & Efficacy of Chemo-radiation While Targeting Treatment, Based on: Original Tumor Characteristics; to be Followed by [Need for] Conventional Post-operative Chemotherapy
Tidsram: 12/2014 (up to 12 years)
|
12/2014 (up to 12 years)
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
To Assess the Pathological Response Rate and Compare it to That Achieved in Our Previous Phase I-II Trials of Concurrent Chemo-radiation.
Tidsram: 12/2014 (up to 12 years)
|
No data displayed because Outcome Measure has zero total participants analyzed.
|
12/2014 (up to 12 years)
|
|
To Store Core Biopsies of the Original Tumor Before and After Treatment (From the Surgical Specimen) for Future Molecular Biology Studies in LABC.
Tidsram: 12/2014 (up to 12 years)
|
No data displayed because Outcome Measure has zero total participants analyzed.
|
12/2014 (up to 12 years)
|
|
To Acquire Descriptive Information on Patient Adherence to Therapy and on Quality of Life During Treatment.
Tidsram: 12/2014 (up to 12 years)
|
Data were not collected as PI left institution prior to enrollment completion.
Planned Statistical analysis was not performed for this secondary outcome measure.
|
12/2014 (up to 12 years)
|
Samarbetspartners och utredare
Det är här du hittar personer och organisationer som är involverade i denna studie.
Sponsor
Studieavstämningsdatum
Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.
Studera stora datum
Studiestart
1 juni 2002
Primärt slutförande (Faktisk)
2 december 2014
Avslutad studie (Faktisk)
2 december 2014
Studieregistreringsdatum
Först inskickad
27 oktober 2014
Först inskickad som uppfyllde QC-kriterierna
20 november 2014
Första postat (Uppskatta)
21 november 2014
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
15 oktober 2018
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
13 september 2018
Senast verifierad
1 september 2018
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
- Hudsjukdomar
- Neoplasmer
- Neoplasmer efter plats
- Bröstsjukdomar
- Bröstneoplasmer
- Molekylära mekanismer för farmakologisk verkan
- Antimetaboliter, antineoplastiska
- Antimetaboliter
- Antineoplastiska medel
- Tubulin modulatorer
- Antimitotiska medel
- Mitosmodulatorer
- Antineoplastiska medel, fytogena
- Antineoplastiska medel, immunologiska
- Paklitaxel
- Trastuzumab
- Capecitabin
Andra studie-ID-nummer
- 10289
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
NEJ
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Ja
Studerar en amerikansk FDA-reglerad produktprodukt
Nej
produkt tillverkad i och exporterad från U.S.A.
Nej
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Bröstcancer
-
Tianjin Medical University Cancer Institute and...Guangxi Medical University; Sun Yat-sen University; Chinese PLA General Hospital och andra samarbetspartnersAvslutadDen kliniska tillämpningsguiden för Conebeam Breast CTKina
-
ETOP IBCSG Partners FoundationAvslutadBreast Cancer Invasive NosItalien
-
Spanish Breast Cancer Research GroupHoffmann-La Roche; Roche Farma, S.AAvslutadBreast Cancer Invasive NosSpanien
-
University Health Network, TorontoAvslutadBreast Cancer Invasive Nos | Primär invasiv bröstcancerKanada
-
Novartis PharmaceuticalsAvslutadMetastaserad bröstcancer (MBC) | Locally Advance Breast Cancer (LABC)Storbritannien, Spanien
-
Pomeranian Medical University SzczecinMaria Sklodowska-Curie National Research Institute of Oncology; Regional...OkändBRCA1-mutation | Breast Cancer Invasive NosPolen
-
McMaster UniversityCanadian Breast Cancer FoundationAvslutadBreast Cancer Invasive Nos | Steg 0 BröstkarcinomKanada
Kliniska prövningar på Radiation Therapy (RT)
-
Alpha Tau Medical LTD.RekryteringLungcancer | Återkommande lungcancerIsrael
-
Alpha Tau Medical LTD.RekryteringHudcancer | Slemhinneneoplasma i munhålan | Neoplasma i mjuk vävnadIsrael
-
Alpha Tau Medical LTD.RekryteringProstata AdenocarcinomIsrael
-
Alpha Tau Medical LTD.RekryteringHudcancer | Slemhinneneoplasma i munhålan | Neoplasma i mjuk vävnadIsrael
-
Alpha Tau Medical LTD.AvslutadMetastaserad bröstcancer | Bröstkarcinom | Invasiv bröstcancer | Fjärrmetastaser.PatologiRyska Federationen
-
Alpha Tau Medical LTD.Avslutad
-
Alpha Tau Medical LTD.RekryteringHudcancer | Slemhinneneoplasma i munhålan | Neoplasma i mjuk vävnadItalien
-
Alpha Tau Medical LTD.Aktiv, inte rekryterandeHudcancer | Slemhinneneoplasma i munhålan | Neoplasma i mjuk vävnadIsrael
-
Alpha Tau Medical LTD.European Organisation for Research and Treatment of Cancer - EORTCHar inte rekryterat ännuSkivepitelcancer i huvud och nacke | SkivepitelcancerIsrael
-
Alpha Tau Medical LTD.RekryteringHudcancer | Slemhinneneoplasma i munhålan | Neoplasma i mjuk vävnadIsrael